Sir: Creatine-containing compounds play an important role in brain energy homeostasis and may have a beneficial effect on brain functioning.
A Case of Pulmonary Thromboembolism and Rhabdomyolysis During Therapy With Mirtazapine and Risperidone
Sir: Mirtazapine may be combined with antipsychotic drugs to treat depressive disorders complicated by psychosis. 1 Mirtazapine is an effective and safe drug in this setting. 2 We describe severe and life-threatening rhabdomyolysis and pulmonary thromboembolism in a patient receiving mirtazapine and risperidone.
Case report. In 2005, Mr. A, a nonobese 40-year-old man (body mass index = 26 kg/m 2 ), developed a syndrome consistent with schizophrenia. He was treated with high doses of risperidone (8 mg); after he subsequently developed a hypokinetic-rigid syndrome, biperiden (2 mg) was added. However, it soon became apparent that the psychosis was followed by a major depressive episode (his Hamilton Rating Scale for Depression [HAM-D] 3 score was 30), and mirtazapine (45 mg) was added.
Outpatient treatment failed, and he was admitted to our psychiatric day clinic (serum levels: risperidone was 5.1 µg/L and 9-OH-risperidone was 47.7 µg/L during therapy with risperidone 7 mg/day). Mirtazapine was increased to 60 mg and risperidone reduced to 3 mg daily. The patient improved, but 6 weeks after starting this combination therapy, he developed acute aching in his left leg and respiratory problems. These led to his admission to a medical hospital, where pulmonary embolism and rhabdomyolysis (creatine kinase level = 4795 U/L) were diagnosed. No hemostatic defect (no abnormalities were found in antithrombin III level, protein C activity, protein S antigen level, or activated protein C resistance) and no evidence for smoking, autoimmune activities, or malignant diseases were detected. During treatment with heparin followed by warfarin, Mr. A recovered. In parallel to the medical therapy, we replaced mirtazapine with reboxetine and replaced risperidone with aripiprazole and achieved a remission of the major depressive episode (his HAM-D score decreased by 24 points to 6). We successfully initiated vocational rehabilitation, and the patient was discharged in a euthymic state 8 weeks after the thromboembolism.
Venous thromboembolism is considered a severe adverse effect of antipsychotic therapy 4 about which we do not have a clear picture regarding predisposing risk factors and biological mechanisms. Thioridazine and clozapine in particular seem to carry a high risk for venous thromboembolism. 5, 6 Two cases with pulmonary thromboembolism during treatment with risperidone have been reported, 7 as well as a further 2 cases with rhabdomyolysis during treatment with risperidone, 8 2 more in combined treatment with risperidone and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 9,10 and 1 during monotherapy with mirtazapine.
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Ours is the first report on the coincidence of rhabdomyolysis and thromboembolism during combined therapy with risperidone and mirtazapine. A malignant neuroleptic syndrome and a central serotonin syndrome can definitely be ruled out, and a careful examination was unable to define any medical cause for the mentioned complications. Therefore, a causal attribution to the psychotropic medication seems to be likely. The pathomechanism, however, remains unclear and might involve pharmacodynamic interactions and changes of blood vessel and thrombocyte function. We recommend awareness regarding these complications and clinical drug monitoring, including creatine kinase monitoring, if patients receive the combination of risperidone and mirtazapine. Sir: Repetitive transcranial magnetic stimulation (rTMS) has been proposed as a new and innovative method for treating neuropsychiatric diseases. Whereas acute antidepressant effects of prefrontal rTMS have been demonstrated in numerous studies, 1, 2 there is almost no reported experience in using rTMS as a maintenance therapy in affective disorders. One session of rTMS per week has been proposed as a treatment schedule for maintenance therapy, and successful outcome results with this treatment schedule were reported in a patient with recurrent depression 3 and in 3 patients with bipolar depression. 4 However, clinical observations in acute phase treatment as well as animal studies suggest that effects of rTMS accumulate in an additive manner when daily stimulations are administered, 5 potentially offering a new way for rTMS maintenance therapy.
On the basis of these considerations, we propose a treatment schedule with 1 week of daily rTMS per month and report the first results of this treatment schedule in a patient suffering from recurrent major depression.
Case report. Ms. A, a 60-year-old woman with a 7-year history of recurrent major depressive disorder (DSM-IV), was referred for a course of rTMS in February 2004. At that time, the patient had experienced her 12th depressive episode. Within the course of the disease, recovery from depressive episodes was increasingly slow and incomplete. Psychosocial stressors contributing to the onset or course of depressive episodes could not be identified despite repeated extensive exploration. Antidepressant medication based on current treatment guidelines, including a variety of distinct antidepressant drugs for adequate duration (at least 12 weeks) such as amitriptyline (100 mg/day), tranylcypromine (60 mg/day), reboxetine (8 mg/day), venlafaxine (300 mg/day), and escitalopram (60 mg/day) as well as augmentation strategies with mood stabilizers such as valproate (1000 mg/day), lamotrigine (200 mg/day), and lithium carbonate (900 mg/day), failed to relieve her depression decisively.
By the time Ms. A was referred for rTMS, her major depressive episode had lasted for 6 months and was characterized by severely depressed mood, recurrent suicidal ideation, anhedonia, insomnia, anxiety, decreased appetite, somatic symptoms, and diurnal variation with depression regularly worse in the morning. Since the current severe episode did not respond to drug treatment, rTMS was considered as an alternative. Prior to this treatment attempt, antidepressant medications, including venlafaxine (150 mg/day), escitalopram (50 mg/day), lithium (225 mg/day), and lamotrigine (100 mg/day), were kept stable for 2 weeks and remained unchanged during rTMS treatment. Due to this convincing clinical effect, we offered rTMS maintenance treatment after the second relapse. On the basis of physiologic considerations of additive efficacy of daily rTMS, 5 we decided to administer 5 sessions of daily rTMS every fifth week. With this treatment schedule, the patient remained free of any further depressive episodes during a follow-up period of 12 months up to the time of this report. HAM-D scores obtained at every treatment week ranged between 0 and 3 points. This relapse-free period is unique in the disease history of the patient and cannot be explained by changes in psychosocial or environmental factors.
We are aware of the limitations of these data, which derive from open treatment in just 1 patient. Nevertheless, the presented case suggests that rTMS administered in a specific temporal pattern provides a promising maintenance treatment in recurrent depression.
The following scales were used at baseline and at 2 and 4 weeks of the study: the Clinician Administered PTSD Scale (CAPS), 5 the Hamilton Rating Scales for Depression (HAM-D) 6 and Anxiety (HAM-A), 7 the Clinical Global Impressions scale (CGI), 8 the Sleep Quality Scale, 9 and the Sheehan Disability Scale (SDS). 10 All patients were treated with creatine monohydrate for 4 weeks (3 g daily in the first week and then 5 g daily for another 3 weeks). Ongoing psychotropic treatment was not altered during the study as there was no clinical need. Statistical analysis included 1-way repeated-measures analyses of variance. All data are presented as mean ± SD.
Results. Ten patients (8 men, 2 women; age range: 43-61 years) participated in the study. Scores on all scales except the SDS and HAM-A improved mildly yet significantly during the study. The CGI scores improved from 4.75 ± 0.7 at baseline to 4.63 ± 0.7 and 4.37 ± 0.9 at 2 and 4 weeks of creatine supplementation, respectively (p = .035 at 4 weeks). All CAPS parameters mildly improved during the study: intrusiveness scores improved the most, and avoidance, the least. Total CAPS score was reduced from 75.6 ± 11 at baseline to 70.1 ± 10 at 2 weeks and 69.8 ± 9 at 4 weeks of creatine consumption (8% improvement, p = .003 at 4 weeks). HAM-D score was reduced from 24.1 ± 5 at baseline to 20.4 ± 6 at 4 weeks of creatine consumption (16% improvement, p = .006). One patient complained of transient weakness at 2 weeks of treatment.
Total CAPS, HAM-D, and HAM-A scores for patients with comorbid DSM-IV-TR major depressive disorder (N = 6) showed greater numerical improvement compared with scores for patients who had no psychiatric comorbidity. The differences were not of statistical significance, probably due to the small sample size.
This preliminary open study of creatine monohydrate demonstrates a modest beneficial effect of this drug on sleep, depressive, and PTSD symptomatology in treatment-resistant PTSD patients. That creatine supplementation also had a beneficial effect on sleep is intriguing, as sleep disturbances are common in PTSD patients and the use of benzodiazepines for such disturbances may carry the risk of abuse and dependence. Sir: The phenomenon of rapid cycling in patients with bipolar disorder has been identified as a marker for high risk of recurrence and resistance to conventional drug treatment.
1 New anticonvulsants are promising agents for the treatment of bipolar disorders, but they are heterogeneous with regard to their efficacy, target symptoms, and adverse event profiles. 2 Vagus nerve stimulation (VNS) therapy is delivered with a device (NCP System; Cyberonics, Houston, Tex.) and has received U.S. Food and Drug Administration approval for adjunctive long-term treatment of chronic or recurrent depression for patients who are experiencing a major depressive episode and have not had an adequate response to 4 or more adequate antidepressant treatments. A recent study did not yield definitive evidence of short-term efficacy for adjunctive VNS in major depression. 3 In contrast, long-term data suggested that VNS is associated with clinically meaningful antidepressant effects. 4 To date, there is no investigation of the effect of VNS on rapid cycling in patients with bipolar disorder.
Case report. Ms. A, a 60-year-old woman, was diagnosed with bipolar II disorder with rapid cycling according to DSM-IV criteria. 5 The patient had no history of drug, alcohol, or substance abuse. She was diagnosed with breast carcinoma in 1990; underwent surgery, chemotherapy, and radiation in the same year; and has been relapse free since then. In the 5 years before implantation (in 2003) of a vagus nerve stimulator, she had a mean (SD) of 8.8 (1.7) depressive, 1.6 (1.0) mixed, and 7.6 (1.0) hypomanic episodes per year. In the 12 months after VNS implantation, Ms. A had 5 depressive, 2 mixed, and 7 hypomanic episodes. After beginning VNS therapy, mean (SD) duration of her depressive episodes decreased from 9.2 (5.1) weeks to 4.6 (3.1) weeks, whereas duration of mixed and hypomanic episodes remained nearly unchanged. After implantation of the stimulator, mean severity of depressive symptoms (measured with the 21-item Hamilton Rating Scale for Depression 6 ) decreased from 24.8 (7. 3) in the year before implantation to 16.9 (6.1) in the year after implantation. At the request of the patient, pharmacologic treatment consisting of valproic acid, 1000 mg, and paroxetine, 40 mg, remained unchanged throughout the 12 months prior to and 12 months after VNS implantation.
This case represents the first, and thus far the only, patient with rapid-cycling bipolar disorder who has been treated with VNS reported in the literature. During VNS treatment, there was a notable decrease in the severity and duration of depressive symptoms. As the only change in therapy during the 12 months prior to and 12 months after VNS implantation was the addition of VNS, it seems likely that the clinical improvement of depressive symptoms was associated with the VNS. However, since total number and severity of hypomanic episodes were not influenced by VNS, this case suggests that this stimulation therapy may preferentially aim at depressive symptoms. Future long-term investigations should also address the use of VNS in a larger sample of rapid-cycling bipolar patients. 
